SXTC News & Events

China SXT Pharmaceuticals announced as part of its Artificial Intelligence Insight Initiative to explore the application of Artificial Intelligence and related digital technologies across the Traditional Chinese Medicine, TCM, raw-material supply chain. This initiative is part of the Company's long-term plan to improve supply chain transparency, operational stability, and quality oversight. "Applying AI to our supply chain management is an important part of our long-term operational planning," said Feng Zhou, Co-Chief Executive Officer and Director of China SXT. "Through the use of digital tools and AI-supported analysis, we aim to enhance supply chain reliability and strengthen our quality assurance capabilities."

China SXT Pharmaceuticals announced that it has entered into a definitive agreement with a single investor for the purchase and sale of an aggregate of 66.67M Class A ordinary shares of the company at a purchase price of 15c per share in a registered direct offering. The aggregate gross proceeds to the company of this offering are expected to be approximately $10M. The transaction is expected to close on or about January 12, subject to the satisfaction of customary closing conditions. Univest Securities is acting as the sole placement agent.